About the Research Roundtable

The mission of the Alzheimer's Association Research Roundtable (AARR) is to advance the research, development and management of new treatments for Alzheimer’s disease.

"I have been attending the Research Roundtable over the past three years and always look forward to these meetings. This is the best meeting forum around for Alzheimer's disease drug developers."

Alzheimer's researcher

The AARR member companies provide leadership and direction to the organization's various activities. Begun in 2003 with four members, the Research Roundtable now includes more than 20 corporate members, whose scientists participate in the Roundtable to contribute to and benefit from the state-of-the-field scientific discourse, debate, and information sharing in order to advance the field of Alzheimer’s research and development. Additional participants include invited investigators from academia and such international government organizations as the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and the National Institutes of Health.

Worldwide impact

Through the Research Roundtable, the Alzheimer's Association® brings together industry leaders with top scientists from around the world to discuss key areas in Alzheimer's science in a precompetitive platform. The Roundtable convenes twice each year for coverage of topics identified by Roundtable members as the most current critical needs. The Roundtable may also focus on specific issues facing the AD field that impact many of the member companies by forming a Task Force or Work Group.

Roundtable members explore a broad range of Alzheimer's cutting edge science topics, including:

  • New data and technologies that may improve the diagnosis of Alzheimer's disease, especially in its earliest and mildest stages.
  • Neuropsychological testing, genetic factors, and biochemical and neuroimaging biomarkers that could contribute to an earlier and more accurate Alzheimer's diagnosis.
  • Lessons learned about clinical trial design that may help shape future clinical trials, including the use of biomarkers for the development of drugs aimed at slowing or stopping the progression of Alzheimer's.
  • The pros and cons of various scales as outcomes measures of clinical trials.

The outputs of Roundtable meetings are published as articles in the Alzheimer's Association's journal, Alzheimer's & Dementia® and have had major impacts in the field of Alzheimer’s disease. For example, the NIA/AA diagnostic criteria for Alzheimer's disease published in 2011 were first highlighted as needed in the field at an AARR meeting.

2018 Members

 

Funding research

The Research Roundtable also sponsors Alzheimer's Association grants. The chosen project is named Research Roundtable Sponsored Grant and the principal investigator of the project is invited to give a progress report at a Roundtable meeting.

The Dale Schenk Alzheimer's Association Research Roundtable Grant Award 

2017 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardees

Shana D. Stites
Study of the Psychosocial Effects of Preclinical Alzheimer’s Disease, University of Pennsylvania

Annamaria Cattaneo 
Characterization of Human Alzheimer’s Disease Brain-Derived Exosomes on Tau Propagation, Boston University Medical Campus

2016 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardees

Holly Cukier
Investigating a Frameshift Deletion in ABCA7 of African Origin Using iPSC, 
University of Miami

Annina Maria DeLeo 
Characterization of Human Alzheimer’s Disease Brain-Derived Exosomes on Tau Propagation, Boston University Medical Campus

2014 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Todd Cohen 
A pathogenic role for tau acetylation in Alzheimer's disease, The University of North Carolina at Chapel Hill

Chun-ling Dai
Role of O-GlcNAcylation in tau pathology and cognitive function
Research Foundation for Mental Hygiene, Inc. at NYS Institute for Basic Research

2013 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Minerva Carrasquillo 
AD Risk Prediction, Cognitive Decline & Gene Regulation at the TREM2 locus
Mayo Clinic Jacksonville

2012 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Jed Meltzer 
Detection of early cortical pathology using MEG and speech analysis
Rotman Research Institute of Baycrest

2011 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Jennifer Manly 
Offspring of ethnically diverse people with and without AD, Columbia University Medical Center

2010 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Maureen Schmitter-Edgecombe 
A Multi-dyad Cognitive Rehabilitation Intervention, Washington State University

2009 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Brenda Plassman 
Middle and Late- Life Predictors of Alzheimer’s Disease in Elderly Twins, Duke University Medical Center


2007 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

Greg Sachs 
AD and Access to Palliative Care, Indiana University

2006 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardee(s)

David Reuben 
Practice Redesign and Partnership to Improve Quality of Dementia Care
The Regents of the University of California

Visit our Grants page to learn more about Association research funding.

Join the Research Roundtable

We invite companies to join the thought leaders in Alzheimer's research at the Research Roundtable. Sponsorship terms are for 12 months beginning on the date of a signed agreement.

For more information, please contact: Jay Thompson, Senior Associate Director Corporate Initiatives at 312.335.5192 or jay.thompson@alz.org.